Prognostic groups of patients followed after surgical operation.

<p>Prognostic groups of patients followed after surgical operation.</p

Levels of FUCAGP and AGP concentrations in serum samples from 12 cancer patients followed over long postsurgical periods.

<p>Patients (A to Q) were classified according to their prognostic statuses. Refer to <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0156277#pone.0156277.t001" target="_blank">Table 1</a> for the details of prognostic status of each patient. Vertical bar indicates the cut-off level of FUCAGP set in this study. Closed and open bars indicate patients underwent chemotherapy and no chemotherapy treatment, respectively.</p

Levels of FUCAGP and AGP concentrations in serum samples from various cancer patients and healthy controls.

<p>FUCAGP, relative abundance of fucosylated tri- and tetraantennary glycans in AGP was obtained from MS analysis. AGP concentrations were determined with an ELISA. † One subject (patient N in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0156277#pone.0156277.g003" target="_blank">Fig 3</a>) was excluded. Samples obtained at one (*) and two (◆) postoperative days. #Patients underwent neoadjuvant chemotherapy. Clinical stages of each patient were shown in the parentheses. Vertical bar indicates the cut-off level of FUCAGP set in this study.</p

Changes of FUCAGP and AGP levels in serum samples from patients followed for long postsurgical periods.

<p>Patients with poor (a) and good (b) prognosis. POD, postoperative days. Solid squares indicate the POD when recurrence and/or metastasis of tumors were clinically determined. Open squares indicate the POD when tumor-free was observed through the computerized tomography (CT) scan. † indicates when the patient died. Each value of tumor markers was measured at the POD indicated with an arrow and numbers with a red-colored letter ‘H’ reveal over the cut-off values indicated in respective instructions. Gray screens on the figure show the duration of chemotherapy with each line of treatment (Ct1—Ct4). Horizontal bars show the cut-off level of FUCAGP set in this study. Refer to <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0156277#pone.0156277.t001" target="_blank">Table 1</a> for the details of prognostic status of each patient.</p

Symbolic representation of α₁-acid glycoprotein (AGP) glycan structures and the determinants of α1,3fucosylated antigen.

<p>One molecule of AGP possesses five glycan chains including diantennary, triantennary and tetraantennary glycans, respectively. All possibilities are shown in brackets and '*'. The common core structure consists of [Man]₃[GlcNAc]₂.*Repeated <i>N</i>-acetyllactosamine structure [(Galβ1,4GlcNAc)_n] attached. See the details in Text.</p

Relationship between Human leukocyte antigen (HLA) class I expression and clinical outcome.

<p>The clinical outcomes of 56 patients with stage III disease. (A; overall survival, B; local control, and C; distant metastasis-free survival). Low HLA class I expression: Grades 0 and 1; high expression: Grades 2 and 3.</p

Human leukocyte antigen (HLA) class I expression in tumor cells.

<p>Representative images showing HLA class I expression by rectal cancer cells. A, Grade 0 expression. B, Grade 1 expression. C, Grade 2 expression. D, Grade 3 expression. Magnification, ×200.</p

Patient and tumor characteristics.

<p>Patient and tumor characteristics.</p

Changes in Human leukocyte antigen (HLA) class I expression after preoperative hyperthermo-chemoradiotherapy (HCRT).

<p>Grades of HLA class I expression in samples from the same patient. A, pre-HCRT specimen; Grade 0. B, post-HCRT specimen; Grade 3. Magnification, ×200. C, HLA class I expression in pre- and post-HCRT specimens. Predictive value was tested using the Wilcoxon signed rank test.</p

Our device had better cleaning ability than that of gauze wiping.

<p>A. Representative endoscopic views: the upper panel shows the image after cleaning the contaminated lens with gauze, and the lower panel shows the contaminated lens after cleaning with the device. B. Luminescence evaluation of residual contaminants on the lens after cleaning by gauze and by the device.</p